| Dr Eileen Larkin Axibal, MD | |
|
1740 E Paris Ave Se, Grand Rapids, MI 49546-6204 | |
| (616) 949-5600 | |
| (616) 949-6571 |
| Full Name | Dr Eileen Larkin Axibal |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Experience | 10 Years |
| Location | 1740 E Paris Ave Se, Grand Rapids, Michigan |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154732386 | NPI | - | NPPES |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Dawm, Plc | 8224032594 | 15 |
News Archive
NorthWest International Healthcare Properties REIT announced today that it has released its results for the three month period ended March 31, 2013.
AstraZeneca today announced the first patient randomized in a Phase 3 clinical trial for selumetinib, an oral, potent, selective MEK inhibitor, being investigated as second-line therapy in patients with advanced or metastatic non-small-cell lung cancer whose tumors are KRAS mutation-positive.
Communicating health information to the "baby boomer" generation might best be done via the internet, especially once they have hit 50, and then 65 years of age, suggest US researchers.
It's a scene that some cancer patients dream about: they celebrate the end of a course of radiation or chemotherapy by ringing a bell, surrounded by family and cheering cancer clinic staff. Indeed, many patients say they love the graduation-like ceremony and the sense of closure it gives them.
› Verified 4 days ago
| Entity Name | Dawm, Plc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932132446 PECOS PAC ID: 8224032594 Enrollment ID: O20060830000113 |
News Archive
NorthWest International Healthcare Properties REIT announced today that it has released its results for the three month period ended March 31, 2013.
AstraZeneca today announced the first patient randomized in a Phase 3 clinical trial for selumetinib, an oral, potent, selective MEK inhibitor, being investigated as second-line therapy in patients with advanced or metastatic non-small-cell lung cancer whose tumors are KRAS mutation-positive.
Communicating health information to the "baby boomer" generation might best be done via the internet, especially once they have hit 50, and then 65 years of age, suggest US researchers.
It's a scene that some cancer patients dream about: they celebrate the end of a course of radiation or chemotherapy by ringing a bell, surrounded by family and cheering cancer clinic staff. Indeed, many patients say they love the graduation-like ceremony and the sense of closure it gives them.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Eileen Larkin Axibal, MD 1740 E Paris Ave Se, Grand Rapids, MI 49546-6204 Ph: (616) 949-5600 | Dr Eileen Larkin Axibal, MD 1740 E Paris Ave Se, Grand Rapids, MI 49546-6204 Ph: (616) 949-5600 |
News Archive
NorthWest International Healthcare Properties REIT announced today that it has released its results for the three month period ended March 31, 2013.
AstraZeneca today announced the first patient randomized in a Phase 3 clinical trial for selumetinib, an oral, potent, selective MEK inhibitor, being investigated as second-line therapy in patients with advanced or metastatic non-small-cell lung cancer whose tumors are KRAS mutation-positive.
Communicating health information to the "baby boomer" generation might best be done via the internet, especially once they have hit 50, and then 65 years of age, suggest US researchers.
It's a scene that some cancer patients dream about: they celebrate the end of a course of radiation or chemotherapy by ringing a bell, surrounded by family and cheering cancer clinic staff. Indeed, many patients say they love the graduation-like ceremony and the sense of closure it gives them.
› Verified 4 days ago
Dr. John E Miner, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1740 E Paris Ave Se, Grand Rapids, MI 49546 Phone: 616-949-5600 Fax: 616-949-6571 | |
Connie M Anderson, PA-C Dermatology Medicare: Accepting Medicare Assignments Practice Location: 750 E Beltline Ave Ne Ste 301, Grand Rapids, MI 49525 Phone: 616-942-9343 Fax: 616-942-2538 | |
Dr. Mary Ann Yurko, MD Dermatology Medicare: Not Enrolled in Medicare Practice Location: 833 Michigan St Ne, Suite 102, Grand Rapids, MI 49503 Phone: 616-459-1440 Fax: 616-459-0313 | |
Mrs. Rachel Ann Zollman, PAC Dermatology Medicare: Accepting Medicare Assignments Practice Location: 750 E Beltline Ave Ne, Suite 301, Grand Rapids, MI 49525 Phone: 616-942-9343 Fax: 616-942-2538 | |
Dipa Suman Patel, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 555 Midtowne St Ne, Suite 301, Grand Rapids, MI 49503 Phone: 616-248-8864 Fax: 616-248-8874 | |
Michelle Mize Emery, MD Dermatology Medicare: Medicare Enrolled Practice Location: 555 Midtowne St Ne, Suite 301, Grand Rapids, MI 49503 Phone: 616-248-8864 Fax: 616-248-8874 |